Ionis Builds Case for Wider Tryngolza Use in Severe Lipid Disorders Following Positive Phase 3 Results on September 03, 2025 Familial chylomicronemia syndrome Hypertriglyceridemia Ionis Pharmaceuticals Lipid Metabolism Disorders Olezarsen Pancreatitis, Acute Severe (severity modifier) Tryngolza +